Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
|
abstract
|
In cancer patients, the clinical response to checkpoint-based
immunotherapy is associated with the composition and functional
quality of the host microbiome. While the relevance of the gut
microbiome for checkpoint immunotherapy outcome has been addressed
intensively, data on the role of the local tumor microbiome are
missing. Here, we set out to molecularly characterize the local
non-small cell lung cancer microbiome using 16S rRNA gene amplicon
sequencing of bronchoscopic tumor biopsies from patients treated
with PD-1/PD-L1-targeted checkpoint inhibitors. Our analyses showed
significant diversity of the tumor microbiome with high proportions
of Firmicutes, Bacteroidetes and Proteobacteria. Correlations with
clinical data revealed that high microbial diversity was associated
with improved patient survival irrespective of radiology-based
treatment response. Moreover, we found that the presence of
Gammaproteobacteria correlated with low PD-L1 expression and poor
response to checkpoint-based immunotherapy, translating into poor
survival. Our study suggests novel microbiome-specific/derived
biomarkers for checkpoint immunotherapy response prediction and
prognosis in lung cancer. In a broader sense, our data draw
attention to the local tumor microbial habitat as an important
addition to the spatially separated microbiome of the gut
compartment.
|
| |
|
|
citation
|
Boesch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S I,
Joerger M, Früh M, Brutsche M. Local tumor microbial signatures and
response to checkpoint blockade in non-small cell lung cancer.
Oncoimmunology 2021; 10:1988403.
|
| |
|
|
type
|
journal paper/review (English)
|
|
date of publishing
|
10-12-2021
|
|
journal title
|
Oncoimmunology (10/1)
|
|
ISSN electronic
|
2162-402X
|
|
pages
|
1988403
|
|
PubMed
|
34912592
|
|
DOI
|
10.1080/2162402X.2021.1988403
|
additional links & downloads
